US2015182672A1PendingUtilityA1
Coatings for implantable medical devices
Assignee: ABBOTT CARDIOVASCULAR SYSTEMSPriority: Mar 20, 2002Filed: Mar 10, 2015Published: Jul 2, 2015
Est. expiryMar 20, 2022(expired)· nominal 20-yr term from priority
A61L 2300/606A61L 31/10A61L 31/16A61L 2300/43A61L 2300/416C08G 18/711C08F 2810/50C08F 8/00C09D 175/04C09D 151/08C08F 2800/10A61K 31/4745A61K 31/337C09D 151/003C08G 18/6212A61K 31/56C08F 8/32C08F 8/30C09D 151/06
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application teaches a coating having a biologically compatible compound conjugated to, or blended with, a polymer, wherein the polymer includes at least one olefin-derived unit and at least one unit derived from a vinyl alcohol, an allyl alcohol, or derivatives thereof.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A coating for a medical device, wherein the coating comprises:
a biologically compatible compound blended with a polymer, wherein the polymer comprises
at least one unit (I)
—CH 2 —CH 2 — (I)
and at least one unit (II)
wherein,
R 1 comprises a component selected from a group consisting of a carboxy, an ester, an ether, an amide, a urethane, an amine, a toluenesulfoester, a 2,2,2-trifluoroethylsulfoester, an epoxy, and a glycidyl group; and
R 2 comprises a component selected from a group consisting of a hydrogen and an alkyl group.
2 . The coating of claim 1 , wherein the polymer comprises:
wherein,
R 1 comprises a component selected from a group consisting of a carboxy, an ester, an ether, an amide, a urethane, an amine, a toluenesulfoester, a 2,2,2-trifluoroethylsulfoester, an epoxy, and a glycidyl group;
R 2 comprises a component selected from a group consisting of a hydrogen and an alkyl group;
the molecular weight of R 1 or R 2 ranges from about 1 to about 30,000 Daltons; and,
the total of m+n is an integer ranging from about 50 to about 7,000.
3 . The coating of claim 1 , wherein the molecular weight of R 1 or R 2 ranges from about 1 to about 30,000 Daltons; and, the total of m+n is an integer ranging from about 50 to about 7,000.
4 . The coating of claim 1 , wherein the molecular weight of R 1 is about 5000 Daltons.
5 . The coating of claim 1 , wherein the alkyl is methyl.
6 . The coating of claim 1 , wherein the polymer comprises
and,
the total of m+n is an integer ranging from about 50 to about 7,000.
7 . The coating of claim 1 , wherein the biologically compatible compound comprises a poly(alkylene glycol), a poly(alkylene glycol) derivative, a protein, a polysaccharide, a superoxide dismutase mimetic, a diazenium diolate, or a combination thereof.
8 . The coating of claim 1 , wherein the biologically compatible compound comprises poly(ethylene glycol).
9 . The coating of claim 1 , wherein the biologically compatible compound is conjugated to a protein or to a polysaccharide.
10 . The coating of claim 9 , wherein the protein comprises albumin.
11 . The coating of claim 9 , wherein the polysaccharide comprises a component selected from a group consisting of hyaluronic acid, heparin, heparin derivatives containing a hydrophobic counter-ion and chitosan.
12 . The coating of claim 7 , wherein the diazenium diolate comprises a component selected from a group consisting of 1,3-propanediamine, N-{4-[1-(3-aminopropyl)-2-hydroxy-2-nitrosohydrazino]butyl}-diazen-1-ium-1,2-diolate and 1-{N-methyl-N-[6-(N-methylammonio)hexyl]amino}diazen-1-ium-1,2-diolate.
13 . The coating of claim 7 , wherein the superoxide dismutase mimetic comprises manganese(II)dichloro-aminoethylthiolated pentaazatetracyclohexacosatriene.
14 . The coating of claim 1 , further comprising a therapeutic substance.
15 . The coating of claim 14 , wherein the therapeutic substance comprises actinomycin D, estradiol, paclitaxel, docetaxel, or rapamycin.
16 . The coating of claim 1 , wherein the medical device comprises a stent.Join the waitlist — get patent alerts
Track US2015182672A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.